Inari Medical, Inc.: M&A transaction — Inari Medical closes $250M acquisition of LimFlow for CLTI limb salvage

Inari Medical, Inc.

Paid ~$238.4M at closing after adjustments; total upfront $250M cash from existing resources.
Up to $165M in contingent milestones payable between 2025-2027 based on commercial/reimbursement goals.
LimFlow is a pioneer in limb salvage for chronic limb-threatening ischemia (CLTI).
Financial statements and pro forma results to be filed within 71 days of this report.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Inari Medical, Inc. completed an acquisition involving LimFlow S.A. for approximately $238.4 million (closed 2023-11-15).

Action: acquisition
Counterparty: LimFlow S.A.
Consideration: approximately $238.4 million
Closing: 2023-11-15

Exact text from the filing

15, 2023, the Company announced that it closed its acquisition of LimFlow (the “ Closing ”). Pursuant to the terms of the Purchase Agreement, the Company delivered approximately $238.4 million to the Sellers at the Closing, after accounting for working capital, indebtedness, cash and transaction expenses. The Company funded the transaction from its existing cash

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001531048-23-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.